Online inquiry

IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ838MR)

This product GTTS-WQ838MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD276 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001024736.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 80381
UniProt ID Q5ZPR3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ838MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12512MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NOE-102
GTTS-WQ6912MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ENB-0040
GTTS-WQ4826MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BT-061
GTTS-WQ15114MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SYD985
GTTS-WQ10525MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY-3015014
GTTS-WQ14552MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SAR156597
GTTS-WQ8717MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ7100MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FE 999301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW